What is Romark?
Founded in 1993 and headquartered in Tampa, Florida, Romark Laboratories operates at the intersection of advanced molecular discovery and clinical development. The company is primarily focused on the identification and commercialization of small molecule therapeutics designed to address unmet medical needs in the treatment of infectious diseases and various forms of cancer. Through a rigorous scientific approach, Romark has established a robust portfolio that bridges the gap between laboratory-based innovation and patient-centric healthcare solutions, positioning itself as a critical contributor to the global biopharmaceutical landscape.
How much funding has Romark raised?
Romark has raised a total of $73.2M across 7 funding rounds:
Private Equity
$23.1M
Private Equity
$9.6M
Private Equity
$15M
Private Equity
$10.8M
Debt
$10.7M
Debt
$2M
Debt
$2M
Private Equity (2009): $23.1M, investors not publicly disclosed
Private Equity (2010): $9.6M, investors not publicly disclosed
Private Equity (2013): $15M, investors not publicly disclosed
Private Equity (2014): $10.8M featuring International Assets Advisory, LLC, Source Capital Group, Inc., and Williams Financial Group
Debt (2015): $10.7M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Romark
International Assets Advisory, LLC
International Assets Advisory, LLC (IAA) is an independent broker-dealer that has been serving financial professionals and institutions since 1982.
Source Capital Group, Inc.
Source Capital Group, Inc. is a boutique investment banking firm that focuses on small to medium-sized transactions, offering expertise in general securities, distressed debt, and business lending.
Williams Financial Group
Founded in 1988, Williams Financial Group is a Dallas-based financial services firm providing a broad range of securities, brokerage, and advisory services to independent financial professionals.
What's next for Romark?
With the recent infusion of capital, Romark is well-positioned to accelerate its clinical trial phases and expand its commercialization infrastructure. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through regulatory milestones, while simultaneously bolstering its internal research capabilities. As the company transitions into this next phase of growth, the focus will remain on scaling its operational capacity to meet the demands of the global market, thereby enhancing its competitive edge in the high-stakes arena of drug development and therapeutic innovation.
See full Romark company page
